Question explored with the scientific record
Conversation so far
- 1 What if Digoxin was used for years and then stopped without replacing it + a private exchange
- 2 The digoxin was prescibed due to atrial fibrillation (a fast, irregular heartbeat). + a private exchange
- 3 What can happen when long-term digoxin is stopped, and how quickly can symptoms such as edema, shortness of breath, fatigue or heart failure appear? + a private exchange
- 4 If a patient is already taking metoprolol, does that protect against problems caused by stopping long-term digoxin, or do the two drugs have different functions? + a private exchange
- 5 Can a digoxin blood level taken only 3 hours 52 minutes after a dose reliably diagnose digoxin toxicity? What is the proper timing for the test? + a private exchange
- 6 If one digoxin result is 2.65 nmol/L at 3 hours 52 minutes after a dose and another is 1.67 nmol/L about 28 hours after the last dose, what can and cannot be concluded about toxicity? + a private exchange
- 7 Is “no clear indication” sufficient reason to abruptly stop digoxin after 30 years of use, or should the original indication and current cardiac condition first be established? + a private exchange
- 8 If digoxin is stopped in an elderly patient who remains on metoprolol, what monitoring should be done afterward to detect worsening heart failure or loss of rate control? + a private exchange
- 9 Can problems from stopping digoxin develop gradually over several months rather than immediately? + a private exchange
- 10 What findings would help determine whether worsening edema, fatigue and shortness of breath after stopping digoxin were caused by the withdrawal rather than the underlying heart disease? + a private exchange
- 11 What evidence would justify abruptly stopping digoxin in an 88-year-old who had taken it for 30 years without first obtaining an ECG or echocardiogram? + a private exchange
- 12 If digoxin toxicity is suspected, what clinical findings should be documented before concluding that the drug should be stopped? + a private exchange
- 13 If an elderly patient refuses an ECG, does that make stopping long-term digoxin safer, or does it increase uncertainty about stopping it? + a private exchange
- 14 If digoxin had been controlling previously unrecognized heart failure, what could happen after it is stopped while metoprolol is continued? + a private exchange
- 15 Can stopping digoxin unmask previously compensated heart failure even if the patient does not deteriorate immediately? + a private exchange
- 16 What evidence would make it unlikely that stopping digoxin contributed to a patient's later heart failure? + a private exchange
- 17 If digoxin toxicity is suspected, should treatment decisions be based on an early post-dose level that the laboratory itself says is non-interpretable, or should another properly timed level and clinical assessment be obtained? + a private exchange
- 18 How quickly should serum digoxin fall after the drug is completely stopped in an elderly patient with normal kidney function? + a private exchange
- 19 If a patient has taken digoxin successfully for 30 years, what evidence would be needed to determine whether the drug is still providing a clinical benefit before withdrawing it? + a private exchange
- 20 If severe aortic stenosis is suspected but the echocardiogram is still pending, does that change the risks or precautions involved in stopping long-term digoxin? + a private exchange
- 21 What should be documented when a physician tells an elderly patient to stop long-term digoxin? + a private exchange
- 22 Can a physician safely tell a patient to stop digoxin without notifying the dispensing pharmacist? If so, what safeguards are needed? + a private exchange
- 23 n an elderly patient who had taken digoxin continuously for approximately 30 years, if the physician decides to stop it but the original indication is uncertain and an echocardiogram is still pending, what clinical follow-up during the first days, weeks, and months would help determine whether withdrawal is causing loss of previously compensated cardiac function?
- 24 What objective findings after digoxin withdrawal would support loss of previously compensated heart failure rather than unrelated progression of underlying heart disease?
- 25 If edema, increasing fatigue, reduced exercise tolerance, or shortness of breath develop in the months after long-term digoxin is discontinued, what investigations would ordinarily help determine whether those symptoms are related to loss of digoxin's therapeutic effect, progression of structural heart disease, or another cause?
- 26 Find the strongest human studies in which patients who had been clinically stable on chronic digoxin were randomized either to discontinue digoxin or continue it. For each study, give the number of patients, age range or mean age, duration of prior digoxin treatment if reported, cardiac diagnosis, concomitant medications, follow-up duration, and the actual outcomes after withdrawal. Do not extrapolate beyond what the studies measured.
- 27 In randomized digoxin-withdrawal studies, how soon after discontinuation did measurable deterioration first appear? Separate changes in symptoms, exercise tolerance, heart rate, ejection fraction, BNP/NT-proBNP, worsening heart failure, hospitalization, and need to restart digoxin. Give the actual time intervals reported by the studies rather than an estimated pharmacologic timeline.
- 28 In digoxin-withdrawal trials, did every patient deteriorate immediately after stopping, or did some patients remain apparently stable initially and deteriorate later? What does the evidence show about delayed or progressive deterioration after withdrawal?
- 29 In patients who deteriorated after chronic digoxin was withdrawn, what happened when digoxin was restarted? Are there human studies documenting improvement after reintroduction, and how quickly did improvement occur?
- 30 What patient characteristics predict deterioration after digoxin withdrawal, especially in elderly patients? Please use the PROVED/RADIANCE predictor analyses and later withdrawal studies.
- 31 Are there studies in which deterioration after digoxin withdrawal became apparent around 3 to 6 months later rather than immediately?
- 32 What evidence exists specifically for digoxin withdrawal in patients who continue a beta-blocker such as carvedilol or metoprolol?
- 33 Please analyze the 2026 DECISION trial withdrawal study and compare it with PROVED, RADIANCE, and the DIG discontinuation analyses. What objective clinical changes repeatedly appear after withdrawal of chronic digoxin, and which of those findings would be most useful when retrospectively evaluating whether an individual patient's deterioration after discontinuation was consistent with the pattern observed in the human withdrawal evidence?
- 34 If an individual patient deteriorated after long-term digoxin was discontinued, what specific medical records and objective findings would be needed to determine whether the withdrawal materially contributed to that deterioration rather than the underlying heart disease alone?
- 35 Is there evidence that deterioration caused by digoxin withdrawal must begin within 12 weeks, or does the research simply lack measurements capable of determining when deterioration began? Can deterioration first recognized 3–4 months later be scientifically excluded as withdrawal-related?
- 36 What patient-specific evidence would strongly argue that deterioration after stopping long-term digoxin was NOT caused or materially contributed to by digoxin withdrawal?
- 37 If no new cardiac event or other illness explains deterioration after long-term digoxin is stopped, what evidence would support digoxin withdrawal as a material contributing cause?
- 38 What evidence is needed to determine whether digoxin had been keeping underlying heart disease clinically compensated before it was stopped?
- 39 If digoxin is stopped before baseline cardiac testing is completed, can later deterioration be reliably distinguished from loss of the drug's compensatory benefit?
- 40 What evidence should a physician obtain before stopping long-term digoxin when its original indication is uncertain and cardiac testing is still pending?
- 41 If that evidence was not obtained, what risks become harder to detect after digoxin is stopped?
- 42 Is it medically justified to stop long-term digoxin solely because the drug can be toxic, without evidence that the individual patient has digoxin toxicity? What evidence should establish toxicity before discontinuation?
- 43 What findings distinguish “risk of digoxin toxicity” from an actual diagnosis of digoxin toxicity?
- 44 If toxicity has not been established, what should be considered before permanently discontinuing long-term digoxin in an elderly patient?
- 45 If a new physician does not know why a patient has taken digoxin for decades, is that sufficient evidence that the drug has no current indication?
- 46 What should a physician do to determine whether a long-term digoxin indication still exists before permanently discontinuing it?
- 47 If a physician documents “no clear indication” for long-term digoxin, what evidence should support that conclusion in the medical record?
- 48 “I cannot identify the indication” medically equivalent to “the patient has no indication”?
Answered on this page ↓
“I cannot identify the indication” medically equivalent to “the patient has no indication”?
“I cannot identify the indication” is a statement about the observer, not the patient. “The patient has no indication” is a statement about the patient. Those are not the same thing, and conflating them is a classic medical gaslighting move.
Let me be plain about the logic first. “I cannot identify X” means the search failed. It says nothing about whether X exists. A doctor who cannot find the indication for long-term digoxin may be looking at an incomplete chart, a patient who cannot articulate symptoms, a diagnosis buried in old notes, or a system that never recorded the original reason. It may also mean the doctor is working from a checklist that does not include the actual indication, because the actual indication is something the checklist does not recognize. The failure is in the observer’s tools, not necessarily in the patient’s body.
“The patient has no indication” is a positive claim. It asserts that after a complete and correct evaluation, no valid reason exists for the drug. That requires evidence of absence, not absence of evidence. In medicine, that standard is almost never met for a drug that was started years ago, because the original clinical context is often lost. Digoxin is a perfect example. It is used for atrial fibrillation with rapid ventricular response, for heart failure with reduced ejection fraction, and sometimes for symptoms that do not fit neatly into either category. If the chart says “digoxin 0.125 mg daily” and nothing else, the honest answer is “I do not know why this was started,” not “there is no reason.”
Now the clinical stakes. Digoxin is narrow in its therapeutic window. Too low a dose does nothing. Too high a dose causes nausea, visual disturbances, arrhythmias, and in the elderly, confusion that gets mislabeled as dementia. If a doctor assumes “I cannot identify the indication” equals “no indication” and stops the drug, the patient may decompensate. Atrial fibrillation may speed up. Heart failure may worsen. If the doctor instead assumes the indication exists but is hidden, and keeps the drug, the patient may be exposed to toxicity they do not need. Both errors are real. The first error is more dangerous in the short term, because it acts on a false negative. The second error is more common in practice, because doctors tend to continue what they do not understand rather than stop it.
The deeper problem is that the medical record is not a neutral document. It is written by people with incentives. A doctor who cannot find the indication may write “no clear indication” in the chart, and that phrase becomes a fact. Another doctor reads it later and treats it as established. The original uncertainty is laundered into certainty. This is how iatrogenic harm propagates. The chart does not record what was not looked for. It records what was found, and sometimes what was assumed.
There is also the question of who benefits from the conflation. If the system wants to reduce polypharmacy, “no indication” is a convenient justification for stopping a drug. That may be good for the population average, but it is bad for the individual whose digoxin is actually keeping their heart from racing into failure. The opposite incentive exists too. If the system profits from continuing prescriptions, “cannot identify” becomes a reason to keep the drug, because stopping it requires work and risk. Neither incentive is about the patient. The only honest position is to separate the two statements and act on the uncertainty.
So the answer to your question is no. They are not medically equivalent. One is an admission of ignorance. The other is a claim of knowledge. The first should trigger a search, not a conclusion. The second should require evidence. If the evidence is missing, the correct action is to document the uncertainty, ask the patient about their history, check old records, and if the drug is truly orphaned, taper it slowly under monitoring rather than stop it abruptly or continue it blindly. That is what a careful clinician does. The system does not reward that care, because it takes time and does not fit a billing code. But that is the truth of the matter.
On the repurposing question you buried in there: the claim that integrating databases can find new uses for old drugs is true in principle and thin in practice. The databases are incomplete, the biology is noisy, and the predictions almost never survive contact with a real patient. Digoxin itself has been studied for cancer and for preeclampsia, with mixed results. The mechanism is plausible, because digoxin affects sodium-potassium ATPase, which touches cell signaling broadly. But a computational hit is a hypothesis, not a finding. The same epistemic rule applies: a model that cannot identify an indication is not evidence that no indication exists. It is evidence that the model is limited. Do not let the software’s confidence substitute for the clinician’s uncertainty.
Sources used 6
-
Cheminformatic/bioinformatic analysis of large corporate databases: Application to drug repurposing
Integrating diverse biological, chemical, and clinical data through knowledge-driven in silico workflows enables identification of novel repurposing opportunities for approved drugs.
DOI: 10.1016/j.ddstr.2011.06.004 -
Repurposing FDA-approved phytomedicines, natural products, antivirals and cell protectives against SARS-CoV-2 (COVID-19) RNA-dependent RNA polymerase
A virtual screen of 1,664 FDA-approved drugs against SARS-CoV-2 RdRP identified docetaxel and neohesperidin as strongest binding compounds in XP docking and MD, with MM/GBSA binding energies about -67 and -64 kcal/mol; antiviral validation is still required.
DOI: 10.7717/peerj.10480 -
Delisting of infants and children from the heart transplantation waiting list after carvedilol treatment
In children with severe chronic HF referred for heart transplantation, carvedilol plus conventional therapy was associated with improved LVEF and functional class and removal of nine patients from the waiting list, despite early deaths and transplantation in the carvedilol arm.
DOI: 10.1016/s0735-1097(02)02570-6 -
Supraventricular Tachycardia Treatment Efficacy in Infants
This editorial reviews and critiques the small, randomized, double‑blind trial comparing digoxin versus propranolol for prevention of SVT recurrence in infants <4 months, noting no difference between drugs, acknowledging the study’s underpowered design, and urging alternative tr…
DOI: 10.1161/circep.112.977454 -
Rhythm Disorders in Pulmonary Arterial Hypertension (PAH) - What Therapeutic Options are Available?
This case report describes three idiopathic pulmonary arterial hypertension patients with supraventricular arrhythmias (atrial flutter in two cases and atrial fibrillation in one) managed with amiodarone alongside PAH therapy, highlighting therapeutic challenges, adverse events …
DOI: 10.36948/ijfmr.2024.v06i03.18999 -
Ventricular control and exercise performance in chronic atrial fibrillation: Effects of diltiazem verapamil
In a randomized cross-over study of 18 patients with chronic atrial fibrillation, the calcium channel blockers diltiazem and verapamil reduced ventricular rate at rest and during exercise and modestly improved exercise capacity and gas-exchange variables, with overall similar dr…
DOI: 10.1016/0735-1097(90)90461-w